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Background: Uterine sarcomas are a group of rare tumors that includes different subtypes. Patients 
with histopathological high-grade diseases are at high-risk of recurrence or progression, and have 
poor prognosis. We aim to explore the most appropriate management in patients with uterine high-
grade sarcomas.  
Primary Objective: To assess the efficacy of maintenance treatment with cabozantinib in patients 
with high-grade uterine sarcomas who achieved clinical benefit after standard chemotherapy. 
Study Hypothesis: Maintenance treatment with cabozantinib after standard chemotherapy given as 
an adjuvant treatment after curative surgery, or in locally advanced or metastatic disease, increases 
progression-free survival compared to placebo 
Trial Design: This randomized double blinded phase II trial.  
Major Exclusion/Inclusion Criteria: Adult patients with high-grade undifferentiated uterine sarcomas, 
high-grade endometrial stromal sarcomas, high-grade leiomyosarcoma, and high-grade 
adenosarcoma, FIGO (Federation International gynecologue Obstétricien) stage II/III to IV in stable 
disease or who achieved complete or partial response with doxorubicin +/- ifosfamide, and assigned 
them 1:1 to 60 mg daily cabozantinib (experimental arm) or placebo (control arm), as maintenance 
therapy. Exclusion criteria included low-grade sarcoma. 
Primary endpoint: Progression-free survival at 4 months (4m-PFS).  
Sample Size: The study planned to enroll 90 patients to allow the randomization of 54 patients to 
detect an improvement in 4m-PFS from 50% to 80% with 15% significance level and 85% power. 
Estimated Dates for Accrual Completion: Recruitment started in February 2015, the trial has currently 
enrolled 83 patients, among whom 35 patients have been randomized. The end of recruitment is 
anticipated for December 2020.  
Trial Registration: ClinicalTrials.gov, number NCT01979393.  
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1 Introduction  
 Uterine sarcomas are rare tumors that account for approximately 1% of female genital tract 
malignancies and 8% of uterine cancers with an incidence of approximately 0.4 per 100,000 women 
(1). Uterine sarcomas belong to a heterogeneous group of tumors including leiomyosarcomas as the 
most common subtype (63%), endometrial stromal sarcoma (21%), and less common subtypes 
gathered as undifferentiated uterine sarcoma (2). The 5-year survival estimates for stage I is 76%, for 
stage II, 60%, for stage III, 45%, and for stage IV disease, 29% (3). Histopathology characteristics 
define patients with high-grade diseases at high risk of recurrence, progression, and poor prognosis. 
High Grade Undifferentiated Uterine Sarcoma (HGUtS) and High Grade Endometrial Stromal Sarcoma 
(HGESS) have a very poor prognosis; most patients die from recurrent disease within two years of 
diagnosis. Endometrial stromal sarcomas with YWHAE-FAM22 fusions represent a clinically 
aggressive subtype of endometrial stromal sarcoma classified as high-grade endometrial stromal 
sarcoma, and are distinct from the usual low-grade endometrial stromal sarcoma with JAZF1 
rearrangement and from high-grade undifferentiated uterine sarcomas with no identifiable 
molecular aberration. Undifferentiated sarcomas have been shown to express Platelet Derived 
Growth Factor Receptor-a (PDGFR-a) (4), androgen receptor (AR) (5), and Wilm’s Tumor1 (WT1) (6). 
The management of patients with high-grade metastatic adenosarcomas is similar to the 
management of patients with metastatic high-grade sarcomas (7). 
 For localized disease, standard guidelines include adjuvant chemotherapy with anthracyclines 
+/- ifosfamide in patients with good performance status and poorly differentiated stage I and II 
sarcoma, or in patients with advanced disease (stage III/IV) (8). Typically, management of metastatic 
uterine sarcoma conforms to treatment practice for other metastatic soft tissue sarcomas. Systemic 
treatment for HGUtS paralleled that for adult-type soft tissue sarcomas, using doxorubicin +/- 
ifosfamide as single agents or in combination (9). No consensus for first line chemotherapy regimen 
has been established yet. First-line therapy currently includes doxorubicin, doxorubicin plus 
ifosfamide, gemcitabine, gemcitabine plus docetaxel, with objective response ranging from 17 to 
36% (10-13).  
 Faced with the lack of effective treatments and the poor prognosis in patients with high-
grade undifferentiated uterine sarcomas, new agents need to be investigated. Indeed, chemotherapy 
is currently mainly use as palliative treatment and the best multimodality treatment did not allow 
sustainable results. The benefits of continuous scheme of chemotherapy administration have never 
been demonstrated superior to therapy disruption after first response observed, and related risks 
from cumulative drug-associated toxicities, such as cardiac toxicity associated with doxorubicin may 
be avoided.  
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 A therapy allowing to stabilize disease or to delay progression after prior cytotoxic 
chemotherapy might help the management of sarcoma patients with advanced/metastatic disease. 
Angiogenesis plays an important role in the growth and dissemination of high-grade undifferentiated 
uterine sarcomas and other soft tissue sarcomas. High VEGF (Vascular endothelial growth factor) 
expression has been identified as an independent prognostic factor, increasing risk of metastases and 
decreasing overall survival (14-16). Pazopanib has been approved by the FDA (Food and Drug 
Administration) for patients with advanced soft tissue sarcomas who have received prior 
chemotherapy (17). A randomized phase II investigated regorafenib, a multikinase inhibitor of 
VEGFR1, VEGFR2, VEGFR3, (vascular endothelial growth factor receptor) and tumor cell signaling 
kinases (RET, KIT, PDGFR, and Raf) in patients with metastatic soft tissue sarcomas previously treated 
with anthracycline. In the leiomyosarcoma cohort, progression-free survival was 3·7 months (95%CI 
2·5-5·0) with regorafenib versus 1·8 (1·0-2·8) months with placebo (HR 0·46, 95%CI 0·46-0·80, 
P=0·0045). In the other soft tissue sarcomas groups, progression-free survival was 2·9 months (95%CI 
1·0-7·8) with regorafenib versus 1·0 (0·9-1·9) with placebo (HR 0·46 95%CI 0·25-0·81, P=0·0061) 
(18,19).  
 Cabozantinib (XL184) inhibits the receptor tyrosine kinases VEGFR2, MET, AXL, and RET. 
Preclinical in vivo studies showed pharmacodynamic inhibition of VEGFR2, MET, AXL and RET with 
cabozantinib, associated with tumor growth inhibition and even tumor shrinkage. Cabozantinib 
capsules (140 mg) were approved by the FDA and EMEA (European Medecine Agency) for the 
treatment of patients with progressive, metastatic medullary thyroid cancer and also approved by 
the FDA in patients with advanced renal cell carcinoma who have received prior anti-angiogenic 
therapy. Based on the activity of cabozantinib observed in several malignancies and the activity of 
pazopanib and regorafenib as VEGF-targeting agents in soft tissue sarcomas, maintenance treatment 
after chemotherapy in patients with high-grade uterine sarcomas warrant further exploration.  
2. Methods 
a) Trial Design  
 This randomized double blinded phase II trial aims to evaluate cabozantinib as maintenance 
therapy in women with high-grade uterine sarcomas after stabilized disease or response achieved 
with chemotherapy following surgery or in advanced first line treatment. This trial planned that 54 
patients will be randomized (1:1) to receive either cabozantinib as monotherapy (experimental arm) 
or placebo (control arm). The efficacy of maintenance treatment will be assessed by formal 
comparison between these two arms of the primary endpoint: by progression-free survival at 4 
months (4m-PFS). At progression, cross-over to cabozantinib is permitted. Key secondary endpoints 
include overall survival and toxicity. Study design is reported figure 1. 
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 Patient are registered in a period ranging from 4 weeks before the initiation and no later 
than 12 weeks after the first dose administration of 1st line treatment. This screening step allows 
timely central histological review. Randomization is performed after pathological confirmation by a 
central review board and should occur no later than 12 weeks after last administration of 1st line 
treatment.  
 Eligible patients are randomized to receive either cabozantinib monotherapy or placebo. 
Cabozatinib should start between three and twelve weeks after the end of the doxorubicin-based 
regimen (see Appendix A for allowed regimens and doses of doxorubicin +/- ifosfamide). Protocol 
treatment is given for 2 years or prematurely discontinued for disease progression, diagnosis of a 
second malignancy, patient refusal, toxicity (impeding further protocol therapy), unblinding of the 
study treatment, pregnancy or failure to use adequate contraception. Patients discontinuing therapy 
in the absence of progression should not receive another cancer treatment, unless ethically 
impossible. After documented disease progression according to RECIST 1.1 (Response Evaluation 
Criteria in Solid Tumours) (20), unblinding of treatment allocation is allowed. Subjects receiving 
cabozantinib shall be treated at investigator discretion. Subjects receiving placebo shall be offered 
the option of receiving cabozantinib. This cross-over is not mandatory and left at the investigator 
decision.  
 The study was approved by the appropriate Institutional Review Board (IRB), and patients 
provided written informed consent for trial-specific procedures. The trial is registered with 
ClinicalTrials.gov, number NCT01979393.This study is funded from donations from the family de 
Spoelbergh and by La Ligue Nationale contre le Cancer from France. In addition, Exelixis, Inc. is 
providing Cabozantinib for this study. Study sites are members of the International Rare Cancer 
Initiative (IRCI). IRCI is a strategic collaboration between Cancer Research UK, the UK National 
Institute for Health Research Cancer Research Network (NCRN), the US National Cancer Institute 
(NCI), the European Organisation for Research and Treatment of Cancer (EORTC) and the French 
National Institute of Cancer (INCa). IRCI aims to facilitate the development of clinical trials in patients 
with rare cancers. EORTC initiated this trial through a collaboration between the EORTC Soft Tissue 
Bone Sarcoma Group (STBSG) and the EORTC Gynecological Cancer Group (GCG). The protocol was 
developed through the IRCI network with input from all parties, but only the NCRN group was 
involved in the recruitment.  
 
b) Participants 
 Adult patients with high-grade undifferentiated uterine sarcomas, high-grade endometrial 
stromal sarcomas, high-grade leiomyosarcoma, and high-grade adenosarcoma, FIGO stage II and III 
(adjuvant chemotherapy proposed), or FIGO stage IV (first line chemotherapy proposed) are eligible 
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for treatment with doxorubicin +/- ifosfamide. Patients should have WHO/ECOG performance status 
0-2 and should be able to swallow and retain oral tablets.  
 Exclusion criteria included low-grade endometrial stromal sarcoma, leiomyosarcoma (low or 
intermediate grade), carcinosarcoma, low-grade adenosarcoma, rhabdomyosarcoma (alveolar or 
embryonal), and soft tissue PNET (Primitive Neuro- Ectodermal Tumor) of uterus/cervix. 
Randomised patients should have histological evidence of high-grade undifferentiated 
uterine sarcomas, high-grade endometrial stromal sarcomas, high-grade leiomyosarcoma, 
and high-grade adenosarcoma centrally confirmed. They should be non-progressive (CR 
(complete response), PR (partial response), SD (stable disease)) after first-line treatment (4 




 The primary objective is to assess the efficacy of maintenance treatment with cabozantinib in 
patients who achieved clinical benefit (CR, PR, or SD) after standard chemotherapy as measured by 
4m-PFS. Secondary efficacy endpoints evaluate PFS, OS, response rate , and duration of response. 
We report safety profile of cabozantinib in patients with high-grade uterine sarcoma (Common 
Terminology Criteria for Adverse Events (CTCAE) v4.0). Exploratory objectives are to evaluate the 
response rate to doxorubicin-based chemotherapy for patients with measurable disease and to 
evaluate Health-Related Quality of Life (HRQoL) in each arm. 
 
d) Sample size 
 Using a 1-sided Fisher exact test, stratified on adjuvant versus metastatic disease, and 
response at end of chemotherapy, 54 patients are needed to detect an increase from 50% to 80%, 
with 85% power and a 15% significance level. Using such design characteristics, but assuming 
progression-free survival rate at 4 months for the control arm of 60%, an improvement of 28% (i.e. 
from 60% to 88%) could be detected. In order to randomize the required 54 patients, a total of 90 
patients should be registered. A total of 35 progression-free survival events at the time of final 
analysis is expected. This would allow to show a HR=0.49 with a 1-sided test at 15% significance level 
with 85% power. 
 
e) Randomization and blinding  
 A minimization technique is used to randomize the patients between the two treatment 
arms, stratified on collaborative group (EORTC versus NCRN), disease (adjuvant versus metastatic), 
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response after first line chemotherapy (CR, PR versus SD) and operability (operable versus 
inoperable). The method used for treatment allocation is a modified version of the dynamic 
allocation method (21-23) and assigns a treatment arm to each patient at the moment it is entered 
into the clinical trial by choosing among the available treatment arms in such a way that the 
stratification factors are balanced over all the treatment arms within preset constraints. 
i- This triple-blind randomized placebo-controlled phase II trial aims to randomize (1:1) 54 patients to 
receive either cabozantinib monotherapy (experimental arm) or placebo (control arm). Due to the 
rarity of uterine sarcomas, the few data mainly based on small retrospective series (24) were used 
for hypotheses assumptions. We used survival data in endometrial and uterine sarcomas from 
previous EORTC studies to define 4 month-PFS (4m-PFS). We therefore determine a 4m-PFS rate of 
50-60% for the control arm. A comparative phase II design as proposed by Korn et al (25) is 
preferred over a non-comparative design, in established reference outcomes due to the uncertainty 
inherent to these rare cancer populations. The result is a comparative phase III trial design with 
increased error rates. (See sample size) 
ii. The treatment arm allocation procedure is triple-blinded: the patient, the local treatment staff, 
and the trial management are not aware of the treatment. Unblinding of treatment allocation may 
occur after progression. In case of a safety concern affecting a patient, the investigator site can 
request to unblind the patient. 
 
f) Statistical methods 
 The primary analysis will be performed according to the intent to treat principle: all 
randomized patients will be analyzed in the arm they were allocated by randomization. The 
superiority of the experimental arm against the control arm will be tested for 4m-PFS using a 1-sided 
stratified Fisher exact test (26) at the 15% significance level. The estimate of the 85% one-sided 
confidence interval (CI) for the proportion of interest will be derived from the exact binomial 
distribution. If a significant difference is found in the overall population, a preplanned subgroup 
analysis will be made in the adjuvant and metastatic subgroups respectively (closed testing 
procedure). The test in each subgroup will be performed on the primary endpoint as a Fisher exact 
test at 15% significance level. 
 For the secondary endpoints, no formal comparisons between arms will be performed. For 
time-to-event endpoints (PFS, OS and response duration), curves will be estimated using the Kaplan-
Meier technique (27) by treatment arm. Hazard ratios and medians will be displayed with their 95% 
confidence interval. Response rates as per RECIST (version 1.1) will be displayed by treatment arm in 
each subgroup together with their 95% exact confidence interval.  
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Safety data will be displayed by treatment arm in each subgroup for those patients who received at 
least one dose of the protocol treatment. The worst toxicity grade over all cycles according to the 
CTCAE  v4.0 will be displayed by treatment arm.  
 The available power to assess the response rate, progression-free survival and overall 
survival is difficult to estimate as the available sample size will depend on the number of patients 
registered in order to reach the 54 randomizations. Assuming 75 available patients and a response 
rate of 40%, the 95%CI width for the response rate would be 2x6%. A total of 50 events would yield 
approximately 80% power to detect a HR=0.5 in either progression-free survival or overall survival 
assuming a two-sided significance test at 10% and a 50%-50% split between groups of interest.  
 
3. Discussion  
 As of February 25th 2020, 11 out of 11 EORTC sites in 6 countries and 7 out of 11 UK sites 
have been activated for patient recruitment. A total of 82 patients have been registered, 
representing 91% of our target (90 patients), including 35 randomized patients, out of 54 (64%) 
patients expected. Recruitment is scheduled to end in 2020. Figure 2 shows the accrual of registered 
and randomized patients. The screening failure rate is higher than anticipated. In practice, this rate is 
closer to 55% (35 out of 79). The major reasons for non-randomization were a change in histological 
diagnosis by central review and progression during 1st line, accounting together for two thirds of the 
screening failures. This highlights the importance of central review in rare cancers as the histological 
diagnosis was changed in 1 in 3 cases.  
 We can also note the complexity of conducting clinical randomized trials in the field of rare 
cancers. This needs to be a priority not only for industry sponsored trials but also for academic 
groups. Success can nevertheless not be guaranteed as recently demonstrated by the premature 
discontinuation of the randomized phase III trial GOG (Gynecologic Oncologic Group)-0277/IRCI 001 
investigating gemcitabine plus docetaxel followed by doxorubicin versus observation in patients with 
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Appendix A: Regimens and doses for doxorubicin +/- ifosfamide 
Single agent: 
 Doxorubicin 
 Doxorubicin (Adriamycin) 75 mg/m2 iv bolus q3w 
Santoro, A et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line 
treatment of advanced soft tissue sarcomas: A randomized study of the European Organisation for 
Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13:1537  
N.B.: Doxorubicin 50-60 mg/m2 iv bolus q3w OR Doxorubicin 20-25 mg/m2 iv bolus weekly x 3 for 
each cycle up to 6 cycles can be used alternatively, according to the discretion of the responsible 
clinician (Principal Investigator [PI]) at the site, depending on the individual patient. 
Combination chemotherapy: 
 Regimen 1 
Doxorubicin (Adriamycin) 50 mg/m2 iv bolus d1 and Ifosfamide 5 g/m2 iv , d1 with Mesna before, 
during and after in appropriate doses, q3 weeks. Growth factor support to be used at the 
discretion of the PI.  
Le Cesne, A et al. Randomized phase III study comparing conventional-dose doxorubicin plus 
ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-
macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European 
Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin 
Oncol 2000; 18:2676  
 Regimen 2 
Doxorubicin (Adriamycin) 20 mg/m2 x 3, d1-3 (total dose 60 mg/m2), or by continuous IV infusion 
as per the original protocol and Ifosfamide 1.5 g/m2/d iv x 4, d1-4 (total dose 6 g/m2), with Mesna 
before, during and after in appropriate doses, q3 weeks. Growth factor support is advised, the 
type is at the discretion of the PI and institution.  
Worden, FP et al. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and 
granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin 
and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 2005; 23:105. 





Appendix B: FIGO staging for uterine sarcomas (2009) 
Stage Definition 
Leiomyosarcomas and endometrial stromal sarcomasa 
I Tumor limited to uterus 
 IA Less than or equal to 5 cm 
 IB More than 5 cm 
II Tumor extends beyond the uterus, within the pelvis 
 IIA Adnexal involvement 
 IIB Involvement of other pelvic tissues 
III Tumor invades abdominal tissues (not just protruding into the abdomen) 
 IIIA One site 
 IIIB More than one site 
 IIIC Metastasis to pelvic and/or para-aortic lymph nodes 
IV  
 IVA Tumor invades bladder and/or rectum 
 IVB Distant metastasis 
Adenosarcomas 
I Tumor limited to uterus 
 IA Tumor limited to endometrium/endocervix with no myometrial invasion 
 IB Less than or equal to half myometrial invasion 
 IC More than half myometrial invasion 
II Tumor extends beyond the uterus, within the pelvis 
 IIA Adnexal involvement 
 IIB Tumor extends to extrauterine pelvic tissue 
III Tumor invades abdominal tissues (not just protruding into the abdomen). 
 IIIA One site 
 IIIB More than one site 
 IIIC Metastasis to pelvic and/or para-aortic lymph nodes 
IV  
 IVA Tumor invades bladder and/or rectum 
 IVB Distant metastasis 
a Simultaneous endometrial stromal sarcomas of the uterine corpus and ovary/pelvis in association 
with ovarian/pelvic endometriosis should be classified as independent primary tumors. 
